Cargando…

P19-17. Construction of HIV-1 AE subtype gp140 DNA vaccine and immunogenicity evaluation

Detalles Bibliográficos
Autores principales:	Zhang, C, Wan, Y
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767845/ http://dx.doi.org/10.1186/1742-4690-6-S3-P337

Ejemplares similares

P19-06. The first hypervariable loop and HIV-1 neutralizing antibodies elicited by gp140 env immunogens
por: Ching, LK, et al.
Publicado: (2009)

P14-06. Phase 1 safety and immunogenicity randomised controlled trial of a vaginal gp140 vaccine
por: Lewis, DJ, et al.
Publicado: (2009)

P19-01. Pre-clinical immunogenicity of mosaic Asian AE/B HIV-1 DNA vaccine in mice
por: Sirivichayakul, S, et al.
Publicado: (2009)

Differential proviral latency of the HIV-1 subtypes B and AE
por: van der Sluis, Renée M, et al.
Publicado: (2011)

Production and Immunogenicity of Soluble Plant-Produced HIV-1 Subtype C Envelope gp140 Immunogens
por: Margolin, Emmanuel, et al.
Publicado: (2019)

Rate and affinity binding constants determined by SPR spectroscopy reveal differential antigenicity of HIV gp120 and gp140
por: Gearhart, TL, et al.
Publicado: (2012)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

Antigenicity of soluble HIV gp140 trimers reveals differences in solution conformation for differing HIV strains
por: Gearhart, TL, et al.
Publicado: (2012)

P19-42. Engineering, expression and antigenic and immunogenic characterization of novel soluble clade A/B heterotrimeric gp140-envelope glycoproteins
por: Sellhon, G, et al.
Publicado: (2009)

P19-54 LB. Interrogating the membrane-proximal external region (MPER) of HIV-1 gp140
por: Jeffs, S, et al.
Publicado: (2009)

CN54gp140: product characteristics, peclinical and clinical use - recombinant glycoprotein for HIV immunization
por: Katinger, D, et al.
Publicado: (2012)

Antigenicity and immunogenicity of a novel, acute HIV-1 Tanzanian subtype C gp145 envelope protein for clinical development
por: Polonis, V, et al.
Publicado: (2012)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

P17-02. PolyCTLDesigner: the software for constructing highly efficient polyepitope immunogens. Application to HIV-1
por: Antonets, D, et al.
Publicado: (2009)

Optimising CN54gp140 plasmid delivery by comparing intramuscular and intradermal vaccination combinations with and without electroporation
por: Mann, JF, et al.
Publicado: (2012)

Stability and neutralization capacity of a novel mosaic HIV-1 gp140 trimer in a guinea pig model
por: Nkolola, JP, et al.
Publicado: (2012)

Characterization and Immunogenicity of HIV Envelope gp140 Zera(®) Tagged Antigens
por: Ximba, Phindile, et al.
Publicado: (2020)

P19-23. Putative prefusion mechanism of HIV-1 Env revealed by ligand-induced quaternary alterations in o-gp140 trimers
por: Moscoso, CG, et al.
Publicado: (2009)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
por: Mata-Fink, J, et al.
Publicado: (2012)

P17-12. Immunogenicity comparison of dna vaccines encompassing HIV-1 tat, rev, integrase (C-half), vif and nef genes derived from different clades
por: Wan, Y, et al.
Publicado: (2009)

P12-13. Structure-guided design and immunological characterization of immunogen constructs presenting the HIV-1 gp120 V3 loop on a CTB scaffold
por: Totrov, M, et al.
Publicado: (2009)

P11-11. Stable lyophilised gel vehicles for vaginal administration of recombinant C-clade HIV-1 trimeric CN54gp140
por: Donnelly, L, et al.
Publicado: (2009)

P11-12. A novel vaginal ring device for the sustained delivery of recombinant C-clade HIV-1 CN54gp140
por: Morrow, RJ, et al.
Publicado: (2009)

Fusion of CTA and CTB gene to immunogen significantly enhances the immunogenicity of DNA vaccine
por: Ren, X, et al.
Publicado: (2012)

Enhanced Immunogenicity of HIV-1 Envelope gp140 Proteins Fused to APRIL
por: Isik, Gözde, et al.
Publicado: (2014)

Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation
por: Kumar, R, et al.
Publicado: (2012)

P05-07. Evaluation of peripheral and bone marrow B cell responses in rhesus macaques after immunization with soluble HIV-1 gp140 trimers
por: Sundling, C, et al.
Publicado: (2009)

Lymphoproliferative responses to HIV-1 Gag p24 antigen and mitogens in HIV-1 subtype CRF01_AE infected Thai patients and HIV-1 seronegative donors
por: Chuenchitra, Thippawan, et al.
Publicado: (2006)

P11-06. Intravaginal administration of HIV-1ZM96 gp140 augments systemic and mucosal antibody responses following systemic priming with adjuvanted protein
por: Cranage, M, et al.
Publicado: (2009)

Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans
por: Katinger, D, et al.
Publicado: (2012)

Analysis of HIV-1 gp120 quasispecies suggests high prevalence of intra-subtype recombination
por: Kiwelu, IE, et al.
Publicado: (2012)

Inverse dose-response to gp140 YU2 foldon trimer formulated with aluminum phosphate and ISCOMATRIX® adjuvants
por: Wilson, A, et al.
Publicado: (2012)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

P17-15. Immunogenicity studies of chimeric yellow fever 17D viruses carrying HIV-1 p24 antigen
por: Franco, D, et al.
Publicado: (2009)

P11-09. Mucosal vaccination with a transferrin-gp140 conjugate via the nasal but not vaginal route elicits robust systemic and vaginal IgG and IgA responses
por: Mann, JF, et al.
Publicado: (2009)

P02-08. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant
por: Sun, J, et al.
Publicado: (2009)

P17-11. HIV DNA vaccine delivery in association with electroporation in the skin of nonhuman primates
por: Culina, S, et al.
Publicado: (2009)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014)

Retraction: Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector
Publicado: (2020)

P12-01. Construction and characterization of recombinant envelope glycoproteins derived from HIV-1 pre-seroconversion strains as potential vaccine immunogens
por: Reddy, S Mohana Rama, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_mo0hib5p90co69h18qr63r7q55